By Maya Goldman Illustration: Sarah Grillo/Axios Trump administration efforts to tamp down Medicare spending have spawned a high-stakes legal fight over bioengineered wound-care products used for purposes like covering diabetic sores. Why it matters: So-called skin substitutes are a massive cost driver in health care, and this will be a test of the federal government’s ability to actually […]
Medicare’s big-money bandage feud Read More »
A group of autism researchers and advocates have formed a new, independent advisory group with a name that’s so similar to a federal autism group, you can’t assume it’s a coincidence. The Independent Autism Coordinating Committee (I-ACC) will hold its first meeting on March 19, the same day that its federally funded doppelganger, the
Autism researchers form new group, rebuke Kennedy Read More »
Illustration: Natalie Peeples/Axios AI is moving fast, and a wave of hot takes is fueling doomerism and amplifying fears about what tech could do to jobs, power and society, Axios’ Madison Mills writes. Why it matters: When something scares me, I like to focus on what I can control. In this case, that’s my own understanding of AI, as
It was a busy week for Eli Lilly and Novo Nordisk. Things kicked off with news about CagriSema, Novo’s GLP-1 plus amylin therapy. The Danish pharma company announced that in a head-to-head trial testing CagriSema against Lilly’s Zepbound in obesity, Zepbound came out on top. Patients who were taking CagriSema lost 20.2% of their weight after 84
By Maya Goldman Data: CDC; Chart: Axios Visuals Nearly 1 in 10 American adults qualified as severely obese in a sample ending in 2023, according to new data from the CDC. Why it matters: Obesity ranks at or near the top of Americans’ public health concerns and is fueling a surge of demand for GLP-1 drugs. The
Charted: Severely obese adult Read More »
Illustration: Gabriella Turrisi/Axios Multimillion-dollar cell and gene therapies may be providing new hope to patients with debilitating diseases but still are rarely used on people enrolled in employer health plans, an analysis of claims data by the Employee Benefit Research Institute found. Why it matters: As more therapies are approved for a wider range of conditions, employers will have
Gene therapies could squeeze workplace plans Read More »
Fellowship Square Historic Mesa was the first U.S. facility to deploy AI-powered motion detector Paul. Photo: Courtesy of Helpany Two years ago, a handful of assisted living facilities in metro Phoenix added a new member to the team to help reduce resident falls. His name is Paul, and he’s an AI-powered motion detector. Why it matters: Falls are among
A fall-fighting robot Read More »
by Matthew Perrone edited by Andrew Zinin Editors’ notes The GIST Add as preferred source Dr. Marty Makary, commissioner of the Food and Drug Administration speaks at an event on addiction recovery in the Oval Office of the White House, Thursday, Jan. 29, 2026, in Washington, as Attorney General Pam Bondi and Interior Secretary Doug Burgum
FDA will drop two-study requirement for new drug approvals, aiming to speed access Read More »
In the midst of a health crisis a few years ago, patient advocate Samantha Bonsack learned a startling fact: The thyroid-stimulating hormone test — one of the most commonly ordered laboratory blood tests in the country — is not standardized. Depending on which company’s analyzer processes the blood, the same sample can yield results differing
Same blood test, different results Read More »
The Medicare innovation center’s ACCESS (Advancing Chronic Care with Effective, Scalable Solutions) model was met with praise when it was announced last year. The program will test paying providers to help patients manage chronic cardiometabolic, musculoskeletal, and behavioral health conditions. Health care providers will get paid the full price only if they do a good job. It’s an
Medicare ACCESS pricing underscores AI focus Read More »
Vitae, vulputate lorem id egestas neque egestas habitant sit ante nec.
✆ Phone (appointments): 714-639-4013
Email: care@imedmg.com
Address: 615 E Chapman Ave, Suite #300, Orange, CA 92866